Literature DB >> 30685245

Considerations for design and implementation of vaccine field trials for novel foot-and-mouth disease vaccines.

Nicholas A Lyons1, Theodore J D Knight-Jones2, Chris Bartels3, David J Paton4, Giancarlo Ferrari5, Meghan S Vermillion6, Abdullah W Brooks7, Roxann Motroni8, Elizabeth Parker9, Melissa L Hefferin Berquist9, Keith J Sumption3, Eyal Klement10.   

Abstract

Vaccines are commonly used to control Foot-and-Mouth Disease (FMD) in endemic regions and form an important part of contingency plans for FMD-free countries. Conventional FMD vaccines have numerous limitations, and the U.S. government supports the development of next-generation vaccines. In the U.S., vaccine efficacy is typically demonstrated through experimental vaccination and challenge of animals using the World Organization for Animal Health (OIE) standards. Although conventional challenge and immunogenicity studies provide useful information, they have limitations and results do not always accurately predict field performance. Consequently, there is a need to test next-generation vaccines under field conditions to gain a better understanding of field performance to inform policy decisions and support their viability as a commercial product. In June 2017, an expert consultation was organised to discuss and define an optimal field study design for novel FMD vaccines. Cattle were the primary species considered, although parallel strategies for swine and small ruminants were also discussed. Many methodological and logistical considerations in the study design were identified, including: (1) study site selection and the importance of baseline studies to understand exposure risk, (2) ethics of using a placebo and assessing equivalence with conventional vaccines, (3) merits of using individual randomised versus cluster randomised trials, (4) preventive versus reactive vaccination, and (5) methods of randomisation and blinding. The proposed optimal study design was a multicentre (i.e. farm), three-arm, double-blind randomised controlled trial comparing groups receiving the novel vaccine to a conventional vaccine group and a placebo group. Large farms in areas of high exposure risk were identified as ideal study sites, and the primary study outcome was susceptibility to disease or infection, during a six-month observation period, following a single dose of vaccine. This report provides a summary of the important issues to consider when designing a field efficacy study in livestock and proposes a study design that could be utilised for novel FMD vaccines.
Copyright © 2019.

Entities:  

Keywords:  Foot-and-mouth disease; Livestock; Vaccine efficacy; Vaccine evaluation

Mesh:

Substances:

Year:  2019        PMID: 30685245     DOI: 10.1016/j.vaccine.2018.12.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Amber codon is genetically unstable in generation of premature termination codon (PTC)-harbouring Foot-and-mouth disease virus (FMDV) via genetic code expansion.

Authors:  Rongzeng Hao; Kun Ma; Yi Ru; Dan Li; Gaoyuan Song; Bingzhou Lu; Huanan Liu; Yajun Li; Jiaoyan Zhang; Chunping Wu; Guicai Zhang; Haitao Hu; Jianxun Luo; Haixue Zheng
Journal:  RNA Biol       Date:  2021-04-14       Impact factor: 4.652

2.  A Single Dose of Dendrimer B2T Peptide Vaccine Partially Protects Pigs against Foot-and-Mouth Disease Virus Infection.

Authors:  Rodrigo Cañas-Arranz; Mar Forner; Sira Defaus; Patricia de León; María J Bustos; Elisa Torres; Francisco Sobrino; David Andreu; Esther Blanco
Journal:  Vaccines (Basel)       Date:  2020-01-10

Review 3.  Towards improvements in foot-and-mouth disease vaccine performance.

Authors:  Graham J Belsham
Journal:  Acta Vet Scand       Date:  2020-05-20       Impact factor: 1.695

4.  Mincle and STING-Stimulating Adjuvants Elicit Robust Cellular Immunity and Drive Long-Lasting Memory Responses in a Foot-and-Mouth Disease Vaccine.

Authors:  Min Ja Lee; Hyundong Jo; Sung Ho Shin; Su-Mi Kim; Byounghan Kim; Hang Sub Shim; Jong-Hyeon Park
Journal:  Front Immunol       Date:  2019-10-29       Impact factor: 7.561

5.  The HSP70-fused foot-and-mouth disease epitope elicits cellular and humoral immunity and drives broad-spectrum protective efficacy.

Authors:  Hyundong Jo; Bong Yoon Kim; So Hui Park; Hyun Mi Kim; Sung Ho Shin; Seong Yun Hwang; Su-Mi Kim; Byounghan Kim; Jong-Hyeon Park; Min Ja Lee
Journal:  NPJ Vaccines       Date:  2021-03-26       Impact factor: 7.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.